Sitagliptin-based regimen hypothesized non-inferior to liraglutide for A1C control in metformin-treated T2DM
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
Abstract
Sitagliptin-based therapy was hypothesized to be non-inferior to liraglutide for improving A1C in Type 2 Diabetes patients inadequately controlled by metformin alone.